France will begin partially reimbursing the obesity medications Wegovy and Mounjaro starting June 15, 2026 [1], [2].

This move lowers the financial barrier for patients struggling with severe obesity, who previously had to pay the full cost of these treatments out of pocket.

The French Assurance maladie, known as Sécurité sociale, will cover 65% of the cost for eligible patients [1], [2]. These medications typically cost approximately 300€ per month [1]. By providing this subsidy, the government aims to make these medical interventions accessible to those with massive to severe obesity [1], [2].

Eligibility for the reimbursement is not universal. The health authority has established specific conditions that patients must meet to qualify for the subsidy [1], [2]. While the primary criteria focus on the severity of the patient's obesity, some reports suggest additional requirements regarding the prescribing physician may be involved [2].

The decision comes as obesity rates continue to be a public health concern across Europe. By integrating these drugs into the national reimbursement scheme, France is treating severe obesity as a chronic medical condition requiring long-term pharmacological support, rather than a lifestyle issue.

The 65% reimbursement rate applies to the standard monthly price of the drugs [1]. Patients who do not meet the strict eligibility criteria set by the health authority will continue to pay the full market price for the treatments [1], [2].

“France will begin partially reimbursing the obesity medications Wegovy and Mounjaro starting June 15, 2026.”

This policy shift reflects a growing European trend of classifying severe obesity as a treatable medical disease rather than a behavioral failure. By subsidizing GLP-1 receptor agonists, the French government is betting that the long-term reduction in obesity-related comorbidities—such as diabetes and cardiovascular disease—will offset the immediate cost of the medication subsidies.